IO Biotech presented positive preclinical data for a novel peptide vaccine reducing tumor growth

From GlobeNewswire: 2025-02-23 12:07:39

IO Biotech presented findings at the AACR-IO conference for a novel peptide vaccine targeting TGF-β in solid tumors. The vaccine, IO170, reduced tumor growth in pancreatic and prostate cancer models without causing systemic toxicity. This approach aims to modulate TGF-β activity rather than fully inhibit it to enhance anti-tumor activity. The company plans to submit an Investigational New Drug Application to the FDA for further development. IO Biotech is known for its T-win platform, designed to reshape the tumor microenvironment for improved treatment efficacy. The positive results support the continued advancement of immune-modulatory cancer vaccines.



Read more at GlobeNewswire: IO Biotech Announces New Preclinical Data for Additional